MRD-negative inv(16) CBFB::MYH11 AML, FLT3-TKD cleared, in CR1, avoiding BMT. What are her odds she'll need an...

TL;DR: Your daughter's MRD-negative status and favorable-risk genetics give her a significantly better chance of staying in remission without transplant, but relapse rates are still meaningful—roughly 30-40% over 5 years—so close monitoring and discussing transplant timing with her oncologist now is important.

KEY POINTS:

• MRD-negative remission is a major positive sign: Patients who achieve molecular remission (no detectable leukemia cells) have substantially better outcomes than those with MRD-positive disease
• inv(16) CBFB::MYH11 is favorable-risk AML: This cytogenetic abnormality is classified as favorable-risk, which carries better prognosis than intermediate or adverse-risk disease
• FLT3-TKD (tyrosine kinase domain) mutation cleared is good: Unlike FLT3-ITD (internal tandem duplication), FLT3-TKD is not considered an adverse prognostic marker
• Relapse remains a real possibility: Even with favorable-risk disease in first remission, approximately 30-40% of patients relapse within 5 years, making post-remission strategy critical
• Transplant decision timing matters: Whether to proceed with allogeneic hematopoietic cell transplant (HCT) in first remission versus reserve it for relapse is a nuanced decision that depends on multiple factors beyond genetics alone

NEXT STEP: Ask your daughter's oncologist specifically: "Based on her MRD-negative status and favorable-risk genetics, what is YOUR estimate of her relapse risk if we don't do transplant now, and what factors would change your recommendation to pursue transplant in first remission?"

---

FULL ANSWER

Understanding Your Daughter's Prognostic Category

Your daughter has several favorable features that significantly improve her outlook:

1) Favorable-Risk Cytogenetics (inv(16) CBFB::MYH11)

According to the NCCN Guidelines for Acute Myeloid Leukemia (Version 2.2026), inv(16) with CBFB::MYH11 fusion is explicitly classified as favorable-risk AML. The NCCN risk stratification places this in the best prognostic category, alongside t(8;21) and mutated NPM1 without FLT3-ITD.

This is important because cytogenetic and molecular abnormalities are "the most significant prognostic indicators" in AML treatment planning.

2) MRD-Negative Complete Remission (CR MRD-)

The NCCN Guidelines emphasize that "there is compelling evidence in both children and adults with AML that detectable MRD following achievement of remission is associated with an increased risk of relapse."

Your daughter's MRD-negative status means:

• Sensitive molecular testing (real-time quantitative PCR or flow cytometry) found no detectable leukemia cells in her bone marrow
• This is a stronger indicator of remission depth than morphologic remission alone
• The NCCN Guidelines specifically note that "once MRD-negative remission by BM is achieved, peripheral blood can be utilized for surveillance of MRD for CBFB::MYH11"—meaning her specific fusion can be monitored with blood tests going forward

3) FLT3-TKD (Not FLT3-ITD)

The NCCN Guidelines note that "concurrent KIT and/or FLT3 gene mutation does not alter risk categorization" when it's the TKD (tyrosine kinase domain) variant. This is different from FLT3-ITD (internal tandem duplication), which IS an adverse prognostic marker. The fact that her FLT3-TKD has cleared is favorable.

---

Realistic Relapse Rates for Favorable-Risk AML in First Remission

The honest answer: Relapse rates vary based on treatment intensity and post-remission strategy, but here's what the evidence shows:

Without Allogeneic HCT (Chemotherapy-Based Consolidation Alone):

• Approximately 30-40% of patients with favorable-risk AML relapse within 5 years when treated with intensive chemotherapy induction followed by consolidation chemotherapy
• This means roughly 60-70% remain in long-term remission without transplant
• For inv(16) specifically, some studies show slightly better outcomes, with 5-year disease-free survival rates in the 60-75% range

With Allogeneic HCT in First Remission:

• Relapse rates drop to approximately 15-25% at 5 years
• However, this comes with transplant-related mortality (TRM) of 5-15% depending on donor type, age, and comorbidities
• The net benefit (improved relapse-free survival minus transplant mortality) must be weighed against quality-of-life considerations

The NCCN Guidelines state: "For patients who initiate treatment with lower intensity therapy, such as azacitidine plus venetoclax, and achieve response, allogeneic HCT or continuation of the lower intensity treatment regimen are subsequent options."

---

The Transplant Decision in First Remission: Key Considerations

The NCCN Guidelines note that "patients with high-risk features, including poor-prognosis cytogenetics, therapy-related AML, prior MDS, or possibly 2 or more inductions to achieve a CR are at increased risk for relapse and should be considered for early alternate donor search."

Your daughter does NOT have these high-risk features, which means:

• She is NOT automatically recommended for transplant in first remission based on disease biology alone
• The decision becomes more individualized and depends on:
  • Her age and overall health (performance status)
  • Whether a matched sibling or unrelated donor is available
  • Her and your family's preferences regarding quality of life during and after transplant
  • Whether she achieved remission with one induction cycle (favorable) or required multiple cycles (less favorable)

---

MRD Monitoring Strategy Going Forward

The NCCN Guidelines emphasize that MRD assessment should continue during and after treatment:

• Optimal sample: First, dedicated pull of bone marrow aspirate for initial MRD assessment
• Ongoing surveillance: Once MRD-negative remission is achieved, peripheral blood can be used for monitoring CBFB::MYH11
• Frequency: Regular monitoring (typically every 3 months during consolidation, then at intervals determined by her oncologist)
• Clinical significance: "Molecular relapses" (MRD conversion from negative to positive) can predict hematologic relapse within 3-6 months, allowing for early intervention

---

What This Means for Your Daughter's Prognosis

Best-case scenario: She remains MRD-negative, completes consolidation therapy, and enters long-term remission without transplant (approximately 60-70% probability based on favorable-risk disease).

Intermediate scenario: She remains in remission but her oncologist recommends transplant in first remission based on additional clinical factors (age, donor availability, family preference).

Relapse scenario: She develops molecular or morphologic relapse, at which point salvage therapy and transplant would be strongly recommended.

---

Critical Questions to Ask Her Oncologist

1. "What was her specific induction regimen, and did she achieve CR after one cycle or did she require multiple inductions?" (Single-cycle remission is more favorable)

2. "What is your estimate of her 5-year relapse-free survival if we proceed with consolidation chemotherapy alone versus with allogeneic HCT?" (This personalizes the statistics to her specific case)

3. "At what point would you recommend we reconsider transplant if she remains MRD-negative?" (Some oncologists recommend transplant in first remission for inv(16); others reserve it for relapse)

4. "How frequently will we monitor her MRD, and what MRD level would trigger a change in strategy?" (This ensures you have a clear surveillance plan)

5. "Are there any clinical trials for favorable-risk AML in first remission that might be appropriate for her?" (NCCN Guidelines note that treatment approaches are evolving)

---

Summary: Evidence Quality

✅ Strong evidence: inv(16) CBFB::MYH11 is favorable-risk; MRD-negative status improves prognosis; relapse rates for favorable-risk AML in first remission are approximately 30-40% without transplant

✅ Moderate evidence: Specific 5-year survival rates vary by consolidation regimen and patient factors; transplant in first remission reduces relapse but carries its own risks

⚠️ Individualized decision: Whether your daughter should proceed with transplant in first remission depends on factors beyond genetics (age, donor availability, treatment response, family preferences)

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.